Diabetic Nephropathy (Metabolic Disorder) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy – Drugs In Development, 2021, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 32, 9, 1, 37 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aerpio Pharmaceuticals Inc

AIBIOS Co Ltd

Akebia Therapeutics Inc

Algomedix Inc

Antisense Therapeutics Ltd

APT Therapeutics Inc

AptaBio Therapeutics Inc

Araim Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

Betagenon AB

Bird Rock Bio Inc

BLR Bio LLC

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Caladrius Biosciences Inc

CCRP Therapeutics GmbH

Cellmid Ltd

Certa Therapeutics Pty Ltd

ChemoCentryx Inc

Chinook Therapeutics Inc

Corbus Pharmaceuticals Inc

CSL Ltd

cStem Regeneration Pharmaceutical Co Ltd

Curacle Co Ltd

Daiichi Sankyo Co Ltd

DiaMedica Therapeutics Inc

Dimerix Ltd

Frontbio Co Ltd

Future Medicine Co Ltd

GenKyoTex SA

Gilead Sciences Inc

Glycadia Inc

Gmax Biopharm LLC

GNI Group Ltd

Goldfinch Bio Inc

Guangdong East Sunshine Pharmaceutical Co Ltd

Guangzhou Magpie Pharmaceutical Co Ltd

Guangzhou Nanxin Pharmaceutical Co Ltd

Inspyr Therapeutics Inc

Inversago Pharma Inc

Johnson & Johnson

Landos Biopharma Inc

MediPost Co Ltd

Merck & Co Inc

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

Nanjing Aimeifei Biomedical Technology Co Ltd

Novartis AG

Novo Nordisk AS

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Orbsen Therapeutics Ltd

PhytoHealth Corp

Poxel SA

Praetego Inc

ProKidney LLC

Reata Pharmaceuticals Inc

Redx Pharma Plc

Scohia Pharma Inc

Secarna Pharmaceuticals GmbH & Co KG

Serodus ASA

Shanghai Alebund Pharmaceuticals Ltd

siRNAgen Therapeutics Corp

Slate Bio Inc

Sulfateq BV

Teijin Pharma Ltd

Unicyte AG

Vidasym Inc

Wuhan Hamilton Bio-technology Co Ltd

Wuhan LL Science and Technology Development Co Ltd

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Diabetic Nephropathy - Overview

Diabetic Nephropathy - Therapeutics Development

Diabetic Nephropathy - Therapeutics Assessment

Diabetic Nephropathy - Companies Involved in Therapeutics Development

Diabetic Nephropathy - Drug Profiles

Diabetic Nephropathy - Dormant Projects

Diabetic Nephropathy - Discontinued Products

Diabetic Nephropathy - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Diabetic Nephropathy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Diabetic Nephropathy – Pipeline by Aerpio Pharmaceuticals Inc, 2021

Diabetic Nephropathy – Pipeline by AIBIOS Co Ltd, 2021

Diabetic Nephropathy – Pipeline by Akebia Therapeutics Inc, 2021

Diabetic Nephropathy – Pipeline by Algomedix Inc, 2021

Diabetic Nephropathy – Pipeline by Antisense Therapeutics Ltd, 2021

Diabetic Nephropathy – Pipeline by APT Therapeutics Inc, 2021

Diabetic Nephropathy – Pipeline by AptaBio Therapeutics Inc, 2021

Diabetic Nephropathy – Pipeline by Araim Pharmaceuticals Inc, 2021

Diabetic Nephropathy – Pipeline by Astellas Pharma Inc, 2021

Diabetic Nephropathy – Pipeline by AstraZeneca Plc, 2021

Diabetic Nephropathy – Pipeline by Bayer AG, 2021

Diabetic Nephropathy – Pipeline by Betagenon AB, 2021

Diabetic Nephropathy – Pipeline by Bird Rock Bio Inc, 2021

Diabetic Nephropathy – Pipeline by BLR Bio LLC, 2021

Diabetic Nephropathy – Pipeline by Boehringer Ingelheim International GmbH, 2021

Diabetic Nephropathy – Pipeline by Bristol-Myers Squibb Co, 2021

Diabetic Nephropathy – Pipeline by Caladrius Biosciences Inc, 2021

Diabetic Nephropathy – Pipeline by CCRP Therapeutics GmbH, 2021

Diabetic Nephropathy – Pipeline by Cellmid Ltd, 2021

Diabetic Nephropathy – Pipeline by Certa Therapeutics Pty Ltd, 2021

Diabetic Nephropathy – Pipeline by ChemoCentryx Inc, 2021

Diabetic Nephropathy – Pipeline by Chinook Therapeutics Inc, 2021

Diabetic Nephropathy – Pipeline by Corbus Pharmaceuticals Inc, 2021

Diabetic Nephropathy – Pipeline by CSL Ltd, 2021

Diabetic Nephropathy – Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021

Diabetic Nephropathy – Pipeline by Curacle Co Ltd, 2021

Diabetic Nephropathy – Pipeline by Slate Bio Inc, 2021

Diabetic Nephropathy – Pipeline by Sulfateq BV, 2021

Diabetic Nephropathy – Pipeline by Teijin Pharma Ltd, 2021

Diabetic Nephropathy – Pipeline by Unicyte AG, 2021

Diabetic Nephropathy – Pipeline by Vidasym Inc, 2021

Diabetic Nephropathy – Pipeline by Wuhan Hamilton Bio-technology Co Ltd, 2021

Diabetic Nephropathy – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2021

Diabetic Nephropathy – Pipeline by ZyVersa Therapeutics Inc, 2021

Diabetic Nephropathy – Dormant Projects, 2021

Diabetic Nephropathy – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Diabetic Nephropathy, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports